TY - JOUR
T1 - Transferrin receptor 2 is frequently and highly expressed in glioblastomas
AU - Calzolari, Alessia
AU - Larocca, Luigi Maria
AU - Deaglio, Silvia
AU - Finisguerra, Veronica
AU - Boe, Alessandra
AU - Raggi, Carla
AU - Ricci-Vitani, Lucia
AU - Pierconti, Francesco
AU - Malavasi, Fabio
AU - De Maria Marchiano, Ruggero
AU - Testa, Ugo
AU - Pallini, Roberto
PY - 2010
Y1 - 2010
N2 - Under physiological conditions, transferrin receptor 2 (TfR2) is expressed in the liver and its balance is related to the cell cycle rather than to intracellular iron levels. We recently showed that TfR2 is highly expressed in glioblastoma cell lines. Here, we demonstrate that, in these cells, TfR2 appears to localize in lipid rafts, induces extracellular signal-regulated kinase 1/2 phosphorylation after transferrin binding, and contributes to cell proliferation, as shown by RNA silencing experiments. In vitro hypoxic conditions induce a significant TfR2 up-regulation, suggesting a role in tumor angiogenesis. As assessed by immunohistochemistry, the level of TfR2 expression in astrocytic tumors is related to histologic grade, with the highest expression observed in glioblastomas. The level of TfR2 expression represents a favorable prognostic factor, which is associated with the higher sensitivity to temozolomide of TfR2-positive tumor cells in vitro. The endothelial cells of glioblastoma vasculature also stain for TfR2, whereas those of the normal brain vessels do not. Importantly, TfR2 is expressed by the subpopulation of glioblastoma cells with properties of cancerinitiating cells. TfR2-positive glioblastoma cells retain their TfR2 expression on xenografting in immunodeficient mice. In conclusion, our observations demonstrate that TfR2 is a neoantigen for astrocytomas that seems attractive for developing target therapies. Copyright © 2010 Neoplasia Press, Inc. All rights reserved.
AB - Under physiological conditions, transferrin receptor 2 (TfR2) is expressed in the liver and its balance is related to the cell cycle rather than to intracellular iron levels. We recently showed that TfR2 is highly expressed in glioblastoma cell lines. Here, we demonstrate that, in these cells, TfR2 appears to localize in lipid rafts, induces extracellular signal-regulated kinase 1/2 phosphorylation after transferrin binding, and contributes to cell proliferation, as shown by RNA silencing experiments. In vitro hypoxic conditions induce a significant TfR2 up-regulation, suggesting a role in tumor angiogenesis. As assessed by immunohistochemistry, the level of TfR2 expression in astrocytic tumors is related to histologic grade, with the highest expression observed in glioblastomas. The level of TfR2 expression represents a favorable prognostic factor, which is associated with the higher sensitivity to temozolomide of TfR2-positive tumor cells in vitro. The endothelial cells of glioblastoma vasculature also stain for TfR2, whereas those of the normal brain vessels do not. Importantly, TfR2 is expressed by the subpopulation of glioblastoma cells with properties of cancerinitiating cells. TfR2-positive glioblastoma cells retain their TfR2 expression on xenografting in immunodeficient mice. In conclusion, our observations demonstrate that TfR2 is a neoantigen for astrocytomas that seems attractive for developing target therapies. Copyright © 2010 Neoplasia Press, Inc. All rights reserved.
KW - Cancer Research
KW - Oncology
KW - Cancer Research
KW - Oncology
UR - http://hdl.handle.net/10807/112881
UR - http://www.transonc.com/pdf/manuscript/v03i02/neo09274.pdf
U2 - 10.1593/tlo.09274
DO - 10.1593/tlo.09274
M3 - Article
SN - 1936-5233
VL - 3
SP - 123
EP - 134
JO - Translational Oncology
JF - Translational Oncology
ER -